Collectively, these findings underscore TIM-3 as both a checkpoint and a regulatory hub, with ongoing therapeutic innovations aiming to manipulate its signaling, ligand binding, and stability to overcome tumor immune evasion. Here, HAVCR2 is linked to neoplasm.